Biotechs line up for a busy week of IPOs

As skeptics and enthusiasts banter back and forth over whether the biotech industry is seeing a bubble on Wall Street, a number of biotechs aren't waiting around for a definitive answer. In a busy week for IPOs in general, four biotechs are planning to go public this week. Seres Therapeutics leads the bunch with a $100 million offering to support its work on the microbiome. Microstent glaucoma devicemaker Glaukos, a medical device company, is also up alongside Cambridge, MA-based Catabasis and Germany's Pieris, the latest European outfit to land at Nasdaq in search of investors cash. Story

Suggested Articles

The mean increase in visual acuity now stands at 23 letters, well above the level deemed clinically meaningful by the FDA.

The action follows the failure of the anti-B7RP1 antibody in a midphase Sjöogren’s syndrome trial.

Novartis nabs GSK exec for Sandoz CEO; Pfizer oncology exec hops to Aduro as CMO; and Alkermes' former COO will head up ops at Paragon.